AU2002307872A1 - Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine for the treatment of pain - Google Patents
Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine for the treatment of painInfo
- Publication number
- AU2002307872A1 AU2002307872A1 AU2002307872A AU2002307872A AU2002307872A1 AU 2002307872 A1 AU2002307872 A1 AU 2002307872A1 AU 2002307872 A AU2002307872 A AU 2002307872A AU 2002307872 A AU2002307872 A AU 2002307872A AU 2002307872 A1 AU2002307872 A1 AU 2002307872A1
- Authority
- AU
- Australia
- Prior art keywords
- pain
- treatment
- thieno
- pyrimidine
- piperazinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
E OF 4 - ( 2 -FLUOROPHENYD - 6 -METHY -2 - ( 1 - PI PERAZINYL) THIENO ( 2 , 3 -D) PYRIMIDINE FOR THE TREATMENT OF PAIN
Field of the Invention
This invention relates to a new therapeutic use for a known compound. 5 Background of the Invention
4-(2-Fluorophenyl)-6-methyl-2-(l-piperazinyl)thieno[2,3-D]pyrimidine monohydrate hydrochloride is known (see US-A-4695568) and has shown activity as an antidepressant. It has serotonin and noradrenergic reuptake-blocking properties and these may be the mechanism of its action as an antidepressant. The compound also has 5HT-3 0 blocking activity.
Pain can be characterised as mild, moderate or severe. It can be acute or chronic in nature. Acute pain tends to resolve within minutes or days but if it persists beyond two weeks or so it is often termed chronic. Pain can be due to trauma or inflammation, and this is often termed nociceptive pain. However, pain not simply due to these causes but 5 due mainly to nerve dysfunction or dysfunctional processing of sensory impulses is often referred to as neuropathic or neurogenic pain.
Acute nociceptive pain is well managed with non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin if it is mild. For moderate pain, tramadol and codeine are useful. For severe pain, opiates such as morphine work well. 0 Mild to moderate chronic nociceptive pain due to inflammation is usually well managed with NSAIDs and COX-2 inhibitors although these drugs can cause serious gastric ulceration and bleeding. Tramadol is also very effective but can cause nausea, vomiting and constipation. For moderate nociceptive pain, opiates like oxycodone and codeine are useful but they cause constipation. For severe nociceptive pain, opiates such 5 as morphine are the mainstay of treatment despite the risk of respiratory depression and addiction.
Few adequate treatments exist for neuropathic pain, and only gabapentin is licensed for this purpose. New medicines are urgently required for neuropathic pain. There is also a need for safer and stronger analgesics for nociceptive pain. 0 Summary of the Invention
Surprisingly, it has been found that the known compound identified above (referred to herein as MCI-225) has activity in the treatment of pain. Its combination of serotonin
and noradrenergic reuptake blockade and 5HT-3 receptor blockade has not previously been identified as being responsible for activity in pain. It will be appreciated that any suitable form of the active principle may be used, e.g. another salt form, or a prodrug or active metabolite. Description of the Invention
By means of this invention, pain can be treated, e.g. controlled or prevented. For this purpose, the active compound can be formulated in any suitable manner together with a conventional diluent or carrier. The active compound is preferably administered by the oral route; other suitable routes of administration include sublingual/buccal, transdermal, intramuscular, intranasal, rectal, parenteral, subcutaneous, pulmonary and topical. An effective dose of the active agent will depend on the nature and degree of the complaint, the age and condition of the patient and other factors known to those skilled in the art. A typical daily dosage may be 0.1 mg to 5 mg.
A pharmaceutical composition containing the active ingredient may be in the form of a sublingual tablet or patch. Suitable compositions for oral use include tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups and elixirs. Suitable additives include sweetening agents, flavouring agents, colouring agents and preserving agents. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients, e.g. inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated, to form osmotic therapeutic tablets for controlled release. Hard gelatin capsules may include an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin; soft gelatin capsules may include water or an oil medium, for example peanut oil, liquid paraffin or olive oil.
The following study has shown the analgesic activity of MCI-225 at an oral dose of 30mg/kg, in an in vivo model of inflammatory pain. The effect was comparable to that of indomethacin (1 mg/kg) , anNSADD widely used for chronic pain such as arthritic pain. Study
Three groups of rats received vehicle, indomethacin or MCI-225. There were 13 rats in each group. Inflammatory pain was induced following a modified Randall Selitto method and the pain threshold of the inflamed paw was measured using a paw pressure analgesiometer. The threshold for paw withdrawal was measured in grams at 1 and 3 hours post dose. The results are shown in the following Tables.
sd = Standard deviation
Statistical significance of difference from vehicle-treated group: *p<0.05, ** <0.01
The results show that MCI-225 was able to increase the pain threshold by 32.3
g at 1 hour and 66.9 g at 3 hours . There is a statistically significant difference between these values and those for vehicle at the same time intervals. On this basis, MCI-225 is useful for the treatment of inflammatory and other pain.
Claims (4)
1. Use of 4-(2-fluorophenyl)-6-methyl-2-(l-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof for the manufacture of a medicament for the treatment of pain.
2. Use according to claim 1, wherein the salt is the monohydrate hydrochloride.
3. Use according to claim 1 or claim 2, wherein the pain is nociceptive pain.
4. Use according to claim 1 or claim 2, wherein the pain is neuropathic pain.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0112494.0 | 2001-05-22 | ||
GBGB0112494.0A GB0112494D0 (en) | 2001-05-22 | 2001-05-22 | New therapeutic use |
PCT/GB2002/002388 WO2002094249A1 (en) | 2001-05-22 | 2002-05-21 | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine for the treatment of pain |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2005200045A Division AU2005200045A1 (en) | 2001-05-22 | 2005-01-07 | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine for the treatment of pain |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2002307872A1 true AU2002307872A1 (en) | 2003-05-08 |
AU2002307872B2 AU2002307872B2 (en) | 2004-10-07 |
Family
ID=9915109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002307872A Withdrawn - After Issue AU2002307872B2 (en) | 2001-05-22 | 2002-05-21 | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine for the treatment of pain |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP1390022B1 (en) |
JP (1) | JP3749519B2 (en) |
KR (1) | KR20040012808A (en) |
CN (1) | CN1230176C (en) |
AT (1) | ATE359769T1 (en) |
AU (1) | AU2002307872B2 (en) |
BR (1) | BR0209956A (en) |
CA (1) | CA2447465A1 (en) |
DE (1) | DE60219616T2 (en) |
DK (1) | DK1390022T3 (en) |
ES (1) | ES2283598T3 (en) |
GB (1) | GB0112494D0 (en) |
PT (1) | PT1390022E (en) |
SI (1) | SI1390022T1 (en) |
WO (1) | WO2002094249A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
US20040087642A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain |
DE602004005814T2 (en) | 2003-01-13 | 2008-01-10 | Dynogen Pharmaceuticals Inc., Waltham | PROCEDURE FOR TREATING EVILNESS, INFRINGEMENT, ORGANIZATION OR ANY COMBINATION THEREOF |
WO2004062623A2 (en) * | 2003-01-13 | 2004-07-29 | Dynogen Pharmaceuticals, Inc. | Method of treating functional bowel disorders |
EP1539181B1 (en) | 2003-04-04 | 2007-06-27 | Dynogen Pharmaceuticals Inc. | Method of treating lower urinary tract disorders |
EP1795196A3 (en) * | 2003-04-04 | 2008-02-06 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60146891A (en) * | 1984-01-05 | 1985-08-02 | Mitsubishi Chem Ind Ltd | (2,3-d)thienopyrimidine derivative and its salt |
-
2001
- 2001-05-22 GB GBGB0112494.0A patent/GB0112494D0/en not_active Ceased
-
2002
- 2002-05-21 PT PT02771681T patent/PT1390022E/en unknown
- 2002-05-21 KR KR10-2003-7014542A patent/KR20040012808A/en not_active Application Discontinuation
- 2002-05-21 DK DK02771681T patent/DK1390022T3/en active
- 2002-05-21 DE DE60219616T patent/DE60219616T2/en not_active Expired - Fee Related
- 2002-05-21 ES ES02771681T patent/ES2283598T3/en not_active Expired - Lifetime
- 2002-05-21 EP EP02771681A patent/EP1390022B1/en not_active Expired - Lifetime
- 2002-05-21 CA CA002447465A patent/CA2447465A1/en not_active Abandoned
- 2002-05-21 AT AT02771681T patent/ATE359769T1/en not_active IP Right Cessation
- 2002-05-21 AU AU2002307872A patent/AU2002307872B2/en not_active Withdrawn - After Issue
- 2002-05-21 CN CNB028103785A patent/CN1230176C/en not_active Expired - Fee Related
- 2002-05-21 SI SI200230552T patent/SI1390022T1/en unknown
- 2002-05-21 WO PCT/GB2002/002388 patent/WO2002094249A1/en active IP Right Grant
- 2002-05-21 JP JP2002590968A patent/JP3749519B2/en not_active Expired - Fee Related
- 2002-05-21 BR BR0209956-0A patent/BR0209956A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0311677B1 (en) | Cough/cold mixtures comprising non-sedating antihistamine drugs | |
EP0114886B1 (en) | Improved analgesic and anti-inflammatory compositions comprising caffeine | |
Becker et al. | Drug therapy in dental practice: nonopioid and opioid analgesics | |
Ferrer-Brechner et al. | Combination therapy with ibuprofen and methadone for chronic cancer pain | |
EP1992333B1 (en) | Flurbiprofen and muscle relaxant combinations | |
US20120064152A1 (en) | Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same | |
CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
AU2002307872B2 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine for the treatment of pain | |
WO2002026239A1 (en) | Analgesic and glucosamine compositions | |
AU2002307872A1 (en) | Use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine for the treatment of pain | |
US20140296274A1 (en) | Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof | |
RU2463042C2 (en) | Sionergistic pharmaceutical combination for pain treatment (versions) | |
US20040048874A1 (en) | New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine | |
JP2004168692A (en) | New use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2, 3-d]pyrimidine | |
US8034801B2 (en) | Analgesic agent | |
GB2313309A (en) | Domperidone and NSAIDs for the treatment of migraine | |
RU2213561C2 (en) | Analgetic compositions containing non-narcotic analgetic and enhancer of analgesia | |
JP2020019740A (en) | Combination of cox inhibitors with morphinan antagonists | |
Sykes et al. | Nonopioid analgesics in the treatment of pain due to malignant disease | |
McPherson | Pharmacotherapy of Pain in Older Adults: Nonopioids | |
AU2003203346A1 (en) | Non-steroidal anti inflammatory drug and glucosamine combination |